Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin

NCT00850161 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business purposes.

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: aspart
DRUG: Nasulin™

Sponsor

CPEX Pharmaceuticals Inc.